Melanotan II and Peptide Tanning: The Illegal Compounds Behind Gym Blackmarkets

← Back to articles

Melanotan II is a lab-made copy of part of alpha-melanocyte stimulating hormone (α-MSH), the body's natural pigment-stimulating hormone. It was first synthesised at the University of Arizona in the 1980s as an investigational drug. It has never been approved for human use anywhere in the world. Despite that, melanotan II is sold through online peptide suppliers and at the back of gyms as an injectable for tanning, libido, and "fat loss." The safety record explains why no regulator has approved it — and why the UK Medicines and Healthcare products Regulatory Agency (MHRA), Australia's TGA, and most European authorities have publicly warned consumers off it.

What it actually does

Melanotan II is a non-selective agonist at the melanocortin receptor family (MC1R, MC3R, MC4R, MC5R). Activation of MC1R on pigment cells (melanocytes) drives melanin production, which is what produces a tan without UV exposure. Activation of MC3R and MC4R in the brain produces the often-marketed "extras": rapid-onset erections (priapism is a documented adverse event), increased libido, appetite suppression, and nausea (Habbema 2017; PMID 28266027; DOI 10.1111/ijd.13585). The same melanocortin pathway has produced two narrowly approved relatives: afamelanotide (Scenesse®), approved by the FDA and EMA only for adults with erythropoietic protoporphyria as an implantable, dose-controlled drug; and bremelanotide (Vyleesi®), FDA-approved in 2019 for premenopausal hypoactive sexual desire disorder, with a defined safety database (Clayton 2022; PMID 35147466; DOI 10.1089/jwh.2021.0191). Melanotan II is neither of those.

The documented harms

Case reports across dermatology, nephrology, neurology, and toxicology journals describe a striking range of harms following melanotan II self-injection.

• New and rapidly changing pigmented moles (atypical melanocytic naevi): a young woman developed multiple atypical moles within a week of two melanotan injections (Reid 2013; PMID 23914578).
• Eruption of new dysplastic naevi and darkening of existing moles in a patient with prior melanoma: after the patient stopped α-MSH peptide use, the new moles lightened and stopped growing (Cardones 2009; PMID 19380666; DOI 10.1001/archdermatol.2008.623).
• Posterior reversible encephalopathy syndrome (PRES): a young woman developed seizures and characteristic MRI changes after self-injecting melanotan (Kaski 2013; PMID 23648958; DOI 10.7326/0003-4819-158-9-201305070-00020).
• Renal infarction with rhabdomyolysis and acute kidney injury: a literature review and case report linked melanotan II to thrombotic kidney injury via vasoconstrictive and direct toxic mechanisms (Peters 2020; PMID 31953620; DOI 10.1007/s13730-020-00447-z).
• Four melanomas reported in melanotan users across the case-report literature; the causal link is debated, but the pattern of rapidly evolving moles is itself a dermatology red flag (Habbema 2017 review; PMID 28266027; DOI 10.1111/ijd.13585).

Adverse-event signals reported across these papers and pharmacovigilance reviews also include priapism (sustained painful erections), facial flushing, nausea (the most common acute side effect), and persistent focal hyperpigmentation. None of these have been studied in a controlled trial of melanotan II at the doses people actually use.

Product quality is unregulated

Because melanotan II is sold outside any regulatory framework, what's in the vial is not what's on the label. Independent mass-spectrometry analyses of black-market peptide products have repeatedly found wide differences in actual peptide content, bacterial endotoxin contamination, and in some cases the wrong compound entirely (Habbema 2017 review; PMID 28266027). Self-injection outside a medical setting also adds the standard risks of non-sterile injection: injection-site abscesses, cellulitis, and bloodstream infection.

The legal and medical reality

In the United States, melanotan II is not FDA-approved for any indication and may not be legally marketed for human use; FDA has issued warning letters to sellers. In the United Kingdom, the MHRA has repeatedly warned that melanotan II is not licensed and is illegal to supply, and Trading Standards has prosecuted sellers. The Therapeutic Goods Administration in Australia classifies it as a prohibited import. The European Medicines Agency has not authorised it. Possession-for-personal-use sits in a legal grey zone in some countries, but distribution is generally illegal. Crucially, doctors do not have an approved framework to monitor people using melanotan II, and there is no antidote — care is supportive only.

Safer alternatives

For pigmentation: sunless tanners with dihydroxyacetone (DHA) and bronzing cosmetics produce a cosmetic tan with no systemic exposure. For libido or erectile function: licensed options exist — PDE5 inhibitors (sildenafil, tadalafil) for erectile dysfunction, and bremelanotide for premenopausal HSDD in women, both with documented safety monitoring (Clayton 2022; PMID 35147466). For people with erythropoietic protoporphyria: the related compound afamelanotide is medically supervised and licensed for that condition. The appeal of melanotan II is understandable; the risk profile is not.